SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
MEDFORD, N.Y., Sept. 12, 2016 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that John Sperzel, Chembio’s chief executive officer, will make a corporate presentation at the Rodman & Renshaw Conference being held September 11 – 13, 2016, in New York, NY.
Details of the presentation are as follows:
| Rodman & Renshaw 18th Annual Global Investment Conference | |
| Time/Date: | Monday, Sept. 12 at 4:15-4:40 PM ET |
| Location: | The Lotte New York Palace Hotel, New York City |
| Room: | Roswell Room (4th Floor) |
To access the live webcast of Chembio's presentation, please visit the "Calendar of Events" section under the Investors tab at www.chembio.com. Additionally, a replay of the webcast will be available on the Chembio website following the conference.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. The Company's SURE CHECK® HIV 1/2 Assay previously has been exclusively sold in the U.S. as Clearview® Complete HIV 1/2 Assay.
Chembio has developed a patented point-of-care (POC) test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.
Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.
Contacts: Chembio Diagnostics Susan Norcott (631) 924-1135, ext. 125 [email protected] Vida Strategic Partners (investor relations) Stephanie C. Diaz (415) 675-7401 [email protected]
